Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach

Key Takeaways TEM signed a $200M three-way deal with AZN and Pathos to build a multimodal oncology foundation model. The partnership lifts TEM's total remaining contract value to over $1B as of April 2025. TEM also expanded ties with ILMN to advance molecular profiling across all major disease areas.ForTempus AI (TEM) , expanding partnerships with existing customers across each of its product lines is key to its growth. In April 2025, the AI-driven precision medicine company extended its collaboration wit ...